AngioDynamics (NASDAQ: ANGO) Reports Strong Revenue Growth Amidst Focus on Profitability
AngioDynamics surpassed revenue estimates for the fourth consecutive quarter, driven by robust growth in its med tech portfolio. Despite reporting a wider year-over-year loss, the company's earnings per share (EPS) beat analyst expectations. The medical technology firm maintains

- AngioDynamics surpassed revenue estimates for the fourth consecutive quarter, driven by robust growth in its med tech portfolio.
- Despite reporting a wider year-over-year loss, the company's earnings per share (EPS) beat analyst expectations.
- The medical technology firm maintains a strong liquidity position with a current ratio of 2.19, reflecting a balanced approach to investment and profitability.
AngioDynamics (NASDAQ: ANGO) is a leading medical technology company. It specializes in developing and selling innovative devices used in minimally invasive procedures. The company is strategically focused on expanding its market share within the high-growth cardiovascular and interventional oncology sectors, where its advanced products play a crucial role in treating various diseases.
On July 14, 2026, AngioDynamics reported an earnings per share (EPS) of -$0.07. This figure impressively surpassed the analyst estimate of -$0.11. However, as highlighted by Zacks, this does represent a wider loss compared to the -$0.03 per share recorded in the same quarter a year ago.
AngioDynamics also announced strong quarterly revenue of $86.61 million, significantly beating the consensus estimate of $80.24 million. This marks an 8% increase from the $80.16 million reported in the prior-year quarter. AngioDynamics has now consistently surpassed revenue estimates for four consecutive quarters, demonstrating strong operational performance.
This impressive revenue growth is primarily driven by AngioDynamics' robust med tech portfolio, which achieved growth of over 18% for the full year. This strong performance led to record financial results for both the fourth quarter and the entire fiscal year, as noted by BusinessWire.
Management emphasizes its commitment to balancing strategic investment with achieving long-term profitability. The company maintains a healthy current ratio of 2.19. This key financial metric indicates that AngioDynamics possesses more than sufficient short-term assets to cover its short-term liabilities, underscoring a solid liquidity position and financial stability.
Originally published by fmp.
View original article

